Literature DB >> 9001570

Gene-modified tumor cells as cellular vaccine.

S Baskar1.   

Abstract

The identification and characterization of many tumor antigens and the parallel explosion of knowledge of the cellular and molecular mechanisms of antigen recognition by the immune system have given renewed hopes that immunogenetherapy could be a promising modality to treat certain tumors. Many different novel strategies have been developed to derive genetically modified tumor cells and use them as cellular vaccines to induce useful antitumor immunity in a variety of animal tumor models. This review discusses induction of tumor immunity by injecting tumor cells that are genetically engineered to secrete various cytokines and to express major histocompatibility complex molecules and/or costimulatory molecules. While there has been a great success in inducing excellent antitumor immunity in a variety of tumor models, there are some difficulties and limitations in the application of these gene-modified tumor cells for the treatment of preexisting tumors. A number of improvements and modifications are already underway to overcome some of these problems.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9001570     DOI: 10.1007/s002620050318

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  3 in total

Review 1.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: an in vitro study.

Authors:  Shao-Ying Lu; Yan-Fang Sui; Zeng-Shan Li; Jing Ye; Hai-Long Dong; Ping Qu; Xiu-Min Zhang; Wen-Yong Wang; Yu-Song Li
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

3.  Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.

Authors:  A Krause; H F Guo; J B Latouche; C Tan; N K Cheung; M Sadelain
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.